Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult ALL

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Shanghai Jiao Tong University School of Medicine
Information provided by (Responsible Party):
Jiong HU, Shanghai Jiao Tong University School of Medicine Identifier:
First received: September 14, 2011
Last updated: May 9, 2016
Last verified: May 2016
Allogeneic stem cell transplantation is potential curative therapy for adult acute lymphocytic leukemia (ALL). Based on our previous study, the condition with iv-busulfan (iv-BU) and cyclophosphamide (CTX) is feasible with low toxicity and transplantation mortality and long-term survival is comparable to most data reported with slightly higher relapse rate particularly for patients in CR2. In this study, the investigators aim to further improve the conditioning with Fludarabine + iv-BU and to use CTX after stem cell transfusion as consolidation for ALL and graft-versus-host disease (GVHD) prophylaxis.

Condition Intervention Phase
Acute Lymphocytic Leukemia
Drug: FLu-Bu-Cy
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Fludarabine/Busulfan and Post-infusion Cyclophosphamide as Conditioning for Adult Patients With ALL Undergoing Allogeienc Stem Cell Transplantation

Resource links provided by NLM:

Further study details as provided by Shanghai Jiao Tong University School of Medicine:

Primary Outcome Measures:
  • overall survival [ Time Frame: 3-year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • transplantation related mortality [ Time Frame: 3-year ] [ Designated as safety issue: Yes ]
  • relapse rate [ Time Frame: 3-year ] [ Designated as safety issue: No ]
  • overall -survival [ Time Frame: day 100 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 40
Study Start Date: April 2011
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FLu-Bu-Cy
Patients received Fludarabine and iv Busulfan and post-infusion Cyclophosphamide as conditioning
Drug: FLu-Bu-Cy
Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4, CSA 3mg/kg starting after D+5.
Other Name: Study group

Detailed Description:
Patients with adult acute lymphocytic leukemia (ALL) received conditioning with Fludarabine + iv-BU. The GVHD was consisting of D+3 and D+4 CTX after stem cell transfusion. CSA will be added for all patients after D+5.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult acute lymphocytic leukemia in 1st or second remission
  • age 18-60 years
  • with inform consent
  • no contraindication for allogeneic transplantation: active infection, allergy to FLu/Bu/CTX, liver and renal function damage
  • HLA matched related (6/6), unrelated donors (at least 8/10) or mismatched related donor (haplo)

Exclusion Criteria:

  • age less than 18 years or over 60 years
  • liver function/renal function damage (over 2 X upper normal range)
  • with mental disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01435447

Contact: Jiong HU, M.D. 86-21-64370045 ext 601878
Contact: Tang Wei, M.D. 86-21-64370045 ext 601816

China, Shanghai
Blood and Marrow Transplantation Center, Rui Jin Hospital Recruiting
Shanghai, Shanghai, China, 200025
Contact: Jiong HU, M.D.    86-21-64370045 ext 601878   
Sponsors and Collaborators
Shanghai Jiao Tong University School of Medicine
Principal Investigator: Jiong Hu, m.D. Rui Jin Hospital, Shanghai JiaoTong University School of Medicine
  More Information

Responsible Party: Jiong HU, Head, Blood and Marrow Transplantation Center, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine Identifier: NCT01435447     History of Changes
Other Study ID Numbers: RJH-ALL-2011 
Study First Received: September 14, 2011
Last Updated: May 9, 2016
Health Authority: China: Ethics Committee
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Shanghai Jiao Tong University School of Medicine:

Additional relevant MeSH terms:
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Fludarabine phosphate
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic
Antiviral Agents
Anti-Infective Agents processed this record on October 26, 2016